This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific. "The
Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023. AFib is the most common heartrhythm disorder, affecting more than 30 million patients worldwide.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablateheart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. Circulation.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
The robotic technology represented an entirely novel way to address heartrhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
Simultaneously, thanks to the revolutionary work of cardiac electrophysiology (EP) physicians, scientists, and industry, ablative treatment of complex arrhythmias including AF has achieved ever-increasing efficacy and safety.
Expert Consensus Statement and Remote Patient Monitoring Guidelines What does the HeartRhythm Society’s new Expert Consensus Statement say? Author : Kevin Hoffman Founder and CEO Vector Remote Care The post 2023 Expert Consensus Statement for Remote Device Clinics appeared first on Vector Remote.
UC San Diego Health is the first in San Diego to successfully implant the world’s first dual chamber and leadless pacemaker system to help treat people with abnormal heartrhythms. The burst of energy can cause the heart to beat more quickly (in a pacemaker), or it can stop dangerous rapid heartrhythms (in an ICD).
Implementing the 2023 Expert Consensus Statement: A Strategic Roadmap for Device Manufacturer Sales Representatives In the ever-evolving landscape of cardiac device care, keeping pace with guidelines and policies can often seem daunting.
Additionally, this platform integrates parameters such as contact force measurement and ablation indexes for RF and PFA which have proven in preclinical studies to be critical for lesion creation. The Dual Energy STSF Catheter and the TruePulse Generator are under development and not available for sale in any region of the world.
Getty Images milla1cf Fri, 12/08/2023 - 08:17 December 8, 2023 — The American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other leading medical associations, have issued a new guideline for preventing and optimally managing atrial fibrillation (AFib).
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
The patient was started on amiodarone, anticoagulation, and metoprolol, and scheduled for atrial flutter ablation. He underwent ablation in the EP Lab. Determining heart rate is easy when the rate is not overly fast. The above said — it is unusual to encounter a regular SVT rhythm at a rate ≥280/minute.
The combined solutions are expected to enhance performance and streamline workflows for electrophysiologists during catheter ablation procedures to treat atrial fibrillation , AFib. Our mission to combat complex heartrhythm diseases relies on optimizing interoperability. The company has obtained U.S.
Launching the first FDA -approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency 1. In my clinical experience with the catheter, it was designed for AF ablation procedures.
The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system. In the U.S.,
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA). iii] The study reported a low fluoroscopy time of 7.8
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content